Jul 16, 2025 8:05 am EDT LIXTE Biotechnology Holdings Regains Compliance with Nasdaq’s Continued Listing Requirements
Jul 9, 2025 8:05 am EDT New Clinical Findings Published in Scientific Journal Nature Validate LIXTE’s Ongoing Ovarian and Colorectal Cancer Trials
Jul 8, 2025 4:05 pm EDT Lixte Biotechnology Holdings, Inc. Announces the Closing of $1.5 Million Registered Direct Offering
Jul 2, 2025 4:05 pm EDT Lixte Biotechnology Holdings, Inc. Announces the Closing of $5.0 Million Private Placement Priced at the Market
Jul 1, 2025 4:15 pm EDT Lixte Biotechnology Holdings, Inc. Announces $5.0 Million Private Placement Priced at the Market
Mar 31, 2025 8:30 am EDT LIXTE Launches New Study to Determine if Certain Pre-Cancerous Cells Found in an Aging Population Can Be Eliminated by LB-100
Mar 27, 2025 8:30 am EDT LIXTE Biotechnology Provides Update On Progress with Proprietary Compound, LB-100, to Treat Ovarian and Colorectal Cancer
Mar 10, 2025 8:30 am EDT New Findings Show how LIXTE’s Lead Clinical Compound, LB-100, is Metabolized to its Active Form
Feb 25, 2025 8:30 am EST LIXTE Adds Northwestern University’s Lurie Cancer Center as Second Site in Ongoing Clinical Trial for Ovarian Clear Cell Cancer
Feb 13, 2025 10:35 am EST LIXTE Biotechnology Announces Closing of $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
